Disentangling the Effects of Colocalizing Genomic Annotations to Functionally Prioritize Non-coding Variants within Complex-Trait Loci  by Trynka, Gosia et al.
ARTICLE
Disentangling the Effects of Colocalizing
Genomic Annotations to Functionally Prioritize
Non-coding Variants within Complex-Trait Loci
Gosia Trynka,1,2,3,4 Harm-Jan Westra,1,2,3 Kamil Slowikowski,1,2,3,5 Xinli Hu,1,2,3,6 Han Xu,7
Barbara E. Stranger,8,9 Robert J. Klein,10 Buhm Han,1,2,3,11,12 and Soumya Raychaudhuri1,2,3,13,*
Identifying genomic annotations that differentiate causal from trait-associated variants is essential to fine mapping disease loci.
Although many studies have identified non-coding functional annotations that overlap disease-associated variants, these annotations
often colocalize, complicating the ability to use these annotations for finemapping causal variation.We developed a statistical approach
(Genomic Annotation Shifter [GoShifter]) to assess whether enriched annotations are able to prioritize causal variation. GoShifter de-
fines the null distribution of an annotation overlapping an allele by locally shifting annotations; this approach is less sensitive to biases
arising from local genomic structure than commonly used enrichmentmethods that depend on SNPmatching. Local shifting also allows
GoShifter to identify independent causal effects from colocalizing annotations. Using GoShifter, we confirmed that variants in expres-
sion quantitative trail loci drive gene-expression changes though DNase-I hypersensitive sites (DHSs) near transcription start sites and
independently through 30 UTR regulation. We also showed that (1) 15%–36% of trait-associated loci map to DHSs independently of
other annotations; (2) loci associated with breast cancer and rheumatoid arthritis harbor potentially causal variants near the summits
of histone marks rather than full peak bodies; (3) variants associated with height are highly enriched in embryonic stem cell DHSs;
and (4) we can effectively prioritize causal variation at specific loci.Introduction
Functional annotations provide valuable information for
prioritizing potential causal variants within complex-trait
loci identified through genome-wide association studies
(GWASs).1–12 Profiles of such functional genomic annota-
tions, including transcription factor binding sites and
open chromatin regions from hundreds of cell types, are
rapidly becoming available.13–15 But, the most informative
annotation is not always known. The most informative
genomic annotations for fine mapping a particular trait
are most likely related to mechanisms important for that
trait. For example, binding sites for transcription factors
that regulate key pathogenic pathways might prioritize
variants for diseases,5,7 and promoters active in a specific
cell type might be able to prioritize expression quantitative
trait locus (eQTL) variants from that cell type. Informative
annotations such as these can be used for identifying likely
causal variants, and these variants can then in turn be
functionally interrogated for elucidating mechanisms un-
derlying the trait.
Identifying the most informative annotations requires a
robust statistical strategy that controls for two important
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The Astructure of genetic variation near SNP associations and
(2) colocalization of multiple functional genomic annota-
tions. First, trait-associated SNPs often map to regions with
greater gene density, genetic variation, and linkage disequi-
librium(LD) than the restof thegenome. Second, functional
annotations that colocalize are often enriched within trait-
associated loci. For example, DNase-I hypersensitive sites
(DHSs) colocalize with exons,16,17 and regulatory elements
cluster together near andwithin gene transcripts. Therefore,
an observed enrichment of one annotation might be the
consequence of unaccounted colocalization with other
annotation, thus confounding inferences of causality.
We developed Genomic Annotation Shifter (GoShifter),
an enrichment test that controls for local genomic structure.
GoShifter employs an intuitive method that locally shifts
sites of tested features within each locus to generate a null
distribution of annotations overlapping associated variants
by chance. Other methods, such as Genome Structure
Correction (GSC), assess the relationships between genomic
featuresby shifting them.1,18–20AlthoughGSCcanassess the
significanceofoverlapbetween twogenomic features, itdoes
not provide a clear application to individual GWAS loci and
their local LDstructure.Here,weapply the shiftingapproach
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loci. We benchmark the performance of GoShifter against
that of commonly employed matching-based methods.
These methods rely on inferring the enrichment of the
SNP-annotation overlap in the observed data by contrasting
it with the overlap in the null set of SNPs derived by random
samplingof variants fromthegenome. Inorder to control for
plausible genomic confounders, thesemethods sample SNPs
by matching for a selection of defined genomic parameters.
The selection of these parameters is based on the assump-
tions about possible analytical confounders. In contrast,
GoShifter does not require prior knowledge because the
null distribution is derived within the tested loci, ensuring
that the density of SNPs, annotations, and the spatial distri-
bution of genomic features are preserved.
We show that compared with commonly used SNP-
matching-based methods, GoShifter is able to robustly
identify informative annotations under a range of different
scenarios. We show that matching-based approaches are
prone to inflating observed enrichment values: we high-
light that the lack of matching on SNPs in LD can lead to
misleading results. Furthermore, we implemented a strati-
fied test to distinguish contributions from two colocalized
annotations. Using the local-shifting approach, GoShifter
allows prioritization of loci by determining the most
informative functional variants driving the observed
enrichment.Material and Methods
Assessing the Significance of Enrichment
We used three methods to assess the significance of enrichment:
(1) local annotation shifting, (2) stratified local shifting, where
we accounted for colocalization of a secondary annotation, and
(3) SNP matching. We implemented (1) and (2) in GoShifter.
Local Annotation Shifting
To assess the statistical significance of an overlap between trait-
associated SNPs and a genomic annotation X, we first identified
all variants in LD with each index SNP (r2 > 0.8 in 1000 Genomes
Project European [EUR] samples21; Figure 1A) and determined the
median size (in base pairs) of the tested annotation. We defined a
locus as the region between the furthest linked SNPs and extended
this region by twice the median size of the tested annotation. This
ensured a sufficient size for testing the significance of an overlap
within a locus defined by an index variant with no other variants
in linkage. Next, we quantified the proportion of loci in which at
least one SNP in LD overlapped X. We then randomly shifted X
sites within each locus and quantified the proportion of loci over-
lapping X while fixing the locations of the SNPs (Figure 1B). We
generated a null distribution from these proportions by repeating
the shifting process over a large number of iterations. In each iter-
ation, the magnitude of the shift was defined as a random integer
sampled from a uniform distribution between 0 and the size of the
locus in base pairs. We retained shifted annotations within the lo-
cus boundaries by ‘‘circularizing’’ the locus (i.e., as an annotation
was shifted beyond the boundaries of a segment, it re-emerged on
the other side of the segment). Circularization preserves the den-
sity of annotations and their spatial relationship within the tested
region. We computed the p value as the proportion of iterations140 The American Journal of Human Genetics 97, 139–152, July 2, 20for which the number of overlapping loci was equal to or greater
than that for the tested SNPs.
Stratified Enrichment of an Annotation
The stratified enrichment analysis assesses the significance of over-
lap of an annotation X while controlling for any overlap with a
potentially colocalizing annotation Y (see Figure 1). We used a
three-step approach: first, we fragmented each locus on the basis
of the presence of Y while fixing the relative positions of the
SNPs and annotation X. An X annotation site was split if it
partially overlapped Y. Second, we concatenated these fragments,
which yielded two distinct segments: (1) Y, which consisted of
concatenated fragments of annotation Y, and (2) Y, which lacked
annotation Y (Figure 1C). This preserved the relationships and
relative positions among X, Y, and the SNPs in the locus in both
segments. Third, to generate the stratified null distribution for
SNP overlap with X, we randomly shifted X within the Y and Y re-
gions independently and quantified the proportion of loci that
had at least one SNP that overlapped X in either region. To ensure
that an annotation could not fall outside the segment boundaries,
we circularized each of the Yand Y segments. As in the unstratified
test, we defined the p value of the enrichment as the proportion of
iterations where the number of loci with SNPs overlapping X ex-
ceeded the number of loci overlapping X prior to shifting. We
note that, just as any form of stratified statistical analysis, the
spatial restrictions on shifting X in a stratified manner might
reduce power.
SNP Matching
Enrichment can also be determined through SNP matching,
although a variety of parameters are used for matching SNPs in
practice (Table S1). To compare the overlap with the null in a set
of SNPs being tested for enrichment, we matched genomic vari-
ants on gene overlap (GEN), minor allele frequency (MAF; with
5% MAF bins), TSS proximity (bins defined by 500-bp, 2-kb,
5-kb, 10-kb, 20-kb, and 100-kb distances from the nearest TSS),
transcription end site (TES) proximity (bins defined by 1-kb,
2-kb, 5-kb, 10-kb, 20-kb, and 100-kb distances from the TES of
the same gene with the nearest TSS), and the number of SNPs in
LD. If fewer than 20 SNPs were present in the sampling bin with
matched SNPs, we expanded to the nearest LD bins while match-
ing on the other properties. The arbitrary choice of 20 ensured that
we had sufficient numbers of SNPs to sample for each SNP and
relative independence between sample SNP sets. We constructed
the null distribution by repeatedly quantifying the overlap be-
tween the annotation and the matched SNP sets. Then, we calcu-
lated the enrichment p value as the proportion of matched SNP
sets with a number of overlaps equal to or greater than that of
the tested SNPs. Because different genotyping platforms pose
distinct biases because of their designs (efficiency of tagging, allele
frequency of included SNPs, number of SNPs, and physical distri-
bution in the genome), we derived the null distribution by sam-
pling variants from a widely used commercial array (Illumina
Omni 2.5).Quantifying Observed Enrichment by Using
Delta-Overlap
To quantify the effect size of the observed enrichment, we calcu-
lated the ‘‘delta-overlap’’ parameter: the difference between the
observed proportion of loci overlapping an annotation and the
mean of the proportion of loci overlapping the annotation under
the null derived by local shifting. If there is no enrichment, the
observed overlap will be close to the mean overlap under the15
Figure 1. Schematic of the GoShifter Method
(A) To assess the statistical significance of an overlap between trait-associated SNPs and an annotation X, we start by using 1000
Genomes Project data to identify variants in LD (r2 > 0.8) with each index SNP.
(B) We quantify the observed overlap: the proportion of loci where at least one linked SNP overlaps annotation X (shaded boxes). We
estimate the significance of the observed overlap by comparing to a null distribution generated by random shifting of X sites (black
arrows) within each locus. After each shift, we calculate the proportion of loci overlapping the annotation. To ensure that the same num-
ber of shifted annotations remains within locus boundaries, we circularize each region.
(C) To determine the significance of an overlap with annotation X independent of a possibly colocalizing annotation Y, we partition
each locus into two types of fragments: those regions mapped by Y sites (light blue blocks) and those that lack them (denoted as Y; white
blocks). We join the respective Yand Y fragments into two independent continuous segments. To generate the null distribution, we shift
annotation X separately within each of the two segments. For each iteration, we count the proportion of loci where any of the linked
SNPs overlaps annotation X in either Y or Y segments to determine the significance of the observed overlap.null, and delta-overlap will be close to 0. Conversely, larger delta-
overlap values correspond to stronger enrichment. In practice,
delta-overlap is independent of the number of SNPs in LD and
the TSS or TES proximities of associated SNP sets (Figure S1).
Prioritizing Informative Loci by Using the Overlap
Score
In order to identify individual loci where the overlap between a
SNP and an annotationwas particularly informative, we calculated
an ‘‘overlap score’’ for each locus. The overlap score is the probabil-
ity that each locus overlaps an annotation by chance. It is
computed only for the loci that overlap the annotation in the
observed data. Loci with low scores drive significant enrichment
observations and are higher-priority candidates for further func-
tional investigations. We defined the overlap score as ls=n, whereThe Als is the number of shifting iterations for which at least one SNP
within an individual locus overlaps the annotation, and n is the
total number of iterations.
Genomic Annotations
Our study utilized DHS data, histone-modification data, and gene-
annotation data compiled from publicly available resources.
DHSs
We used the DHS data from 80 experiments from ENCODE13
and 137 experiments from the NIH Roadmap Epigenomics
Project14 (Table S2).We downloaded chromatin immunoprecipita-
tion sequencing reads mapped to hg19 (UCSC Genome Browser)
and merged reads from replicate samples. Using a corresponding
input DNA library as the control if available, we ran MACS
v.2.022 with default settings (false-discovery rate [FDR] ¼ 0.01;merican Journal of Human Genetics 97, 139–152, July 2, 2015 141
bandwidth ¼ 300 bp) to identify significant peaks. In total, anal-
ysis of 217 experiments yielded 1,331,772 distinct autosomal
DHSs, collectively spanning 16.4% of the genome. We combined
DHS tracks across all cell types into a single consolidated DHS track
by identifying the genomic positions that overlap DHSs in any cell
type.
Histone Modifications
Similarly, we used MACS v.2.0 to call H3K4me3, H3K4me1, and
H3K9ac peaks in 118, 114, and 50 tissues and cell-type samples,
respectively, from the NIH Roadmap Epigenome14 (see Table S2
for a detailed list of included tissues and cell types). If multiple rep-
licates of the same tissue (input and control) were generated by the
same center, we used these multiple BED files as input for MACS.
For each experiment, we located the start and end of the peaks, as
well as the summit regions (defined as5100 bp around summits)
called by MACS.
Gene Annotations
We defined gene annotations, including genes (whole transcripts
including UTRs), exons, 50 UTRs, 30 UTRs, introns, and promoter re-
gions, on the basis of RefSeq gene coordinates from the UCSC
Genome Browser. We retained genes with at least one exon and at
least one PubMed reference23 to exclude poorly studied genes, pseu-
dogenes, and falsely identified genes. In the resulting set of 18,183
genes,we identified exons, introns, andUTRs.Wedefinedpromoter
regions as the first 500 bp upstream of the TSS. We note that DHS
coverage for different gene features varied: 26% for exons, 73% for
promoters, 75% for 50 UTRs, 22% for 30 UTRs, and 20% for introns.Simulations
To assess GoShifter’s sensitivity and specificity, we (1) defined sets
of SNPs within functional regions, (2) generated sets of variants
tagging these SNPs, as is common in GWASs, and (3) generated
sets of SNPs with variable proportions of functional variants.
Defining Functional SNP Classes
Using a total of 6,830,225 common autosomal SNPs (MAF> 5% in
Europeans in the 1000 Genomes Project), we grouped SNPs into
seven functional categories: nonsynonymous, intronic, 30 UTR,
50 UTR, promoter (<500 bp from the TSS), intergenic (>5 kb
from the TSS), and those residing within DHSs. To identify nonsy-
nonymous variants, we used SIFT.24
Simulating SNP Sets Tagging Defined Functional GWAS Variants
We simulated 1,000 sets of 1,416 SNPs (to match the NHGRI
GWAS Catalog SNP list), selected to overlap each of the predefined
seven functional categories. In each set, variants were randomly
selected from a given functional category. In order to mimic a
typical GWAS approach, we then identified a tagging SNP that
was in LD and was available on a commercial genotyping array
(Illumina Human Omni2.5) for each functional variant. In total,
5,569,657 of the available SNPs were tagged (r2 R 0.5) by
1,218,618 common (MAFR 5%) variants on the Illumina Human
Omni 2.5 array. If multiple SNPs were in LD with the functional
variant, we selected the best tag with the greatest r2. Finally, we
required SNPs in the final set to be more than 100 kb apart from
each other to ensure independence. As an alternative to simu-
lating a sequencing-based study, we also simulated 200 sets of
1,416 causal SNPs for each of the predefined functional categories
by selecting tagging SNPs with strong LD (r2R 0.8) from the EUR
subset of the 1000 Genomes Project data. If multiple SNPs were in
LD with the functional variant, we selected the best tag with the
greatest r2, and we selected the functional SNP itself when no
tag SNP could be selected according to these criteria.142 The American Journal of Human Genetics 97, 139–152, July 2, 20SNP Sets with Variable Proportions of Causal Functional Variants within
DHSs
In addition to defining SNP sets derived from causal variants
within a single annotation, we also defined SNP sets where causal
variants were derived from two separate functional annotations.
In these instances, we selected a proportion of causal variants
from one annotation and selected the remainder from a second
annotation.Associated Variants
Disease-Associated Variants from the NHGRI GWAS Catalog
We obtained trait-associated SNPs from the GWAS Catalog25 on
November 5, 2013. We included only high-frequency (MAF > 5%)
bi-allelic autosomal SNPs with a genome-wide significant (p < 5 3
108) associationwith any trait.We includedonly studieswhere Eu-
ropeans contributed to themajority of the final samples to simplify
LD calculations. We conducted LD calculations across the selected
SNPs by using 379 EUR samples from the 1000 Genomes Project21
and only bi-allelic SNPs with at least five copies of the minor allele.
We ensured that these SNPs were independent by randomly
excluding one SNP for each pair of SNPs if r2> 0.1 or if the distance
between the SNPs was <100 kb. Finally, we excluded phenotypes
with fewer than ten independent SNP associations after ourfiltering
criteria. This resulted in 1,416 SNPs in our test set.
Variants Associated with Height, Rheumatoid Arthritis, and Breast
Cancer
We used 689 SNPs associated with height,26 89 SNPs associated
with rheumatoid arthritis (RA [MIM: 180300]) in Europeans alone
or shared between Europeans and Japanese,27 and 69 SNPs associ-
ated with breast cancer (MIM: 114480).28
eQTLs
We assembled a set of 923,022 cis-eQTL SNPs associated with
whole-blood gene expression at a FDR of 0.5.29 For each reported
eQTL gene, we selected the single SNP most significantly associ-
ated with its expression and then performed LD pruning30 (by us-
ing a window of 1,000 SNPs, sliding by one SNP at a time, and
excluding one SNP in a pair if r2 > 0.1) to ensure independence
of the SNPs in our final SNP set. This resulted in a final dataset
of 6,381 eQTL SNPs.Results
GoShifter Is a Robust Method for Enrichment Testing
To evaluate GoShifter’s performance in prioritizing annota-
tions that identify causal variants,wewould ideally use a set
of trait-associated loci inwhich the causal variants and rele-
vant driving genomic annotations are known. However,
causal variants are known for only a handful of complex-
trait loci. Therefore, to capture a wide range of possible
models of causal variation, we simulated 1,000 sets of
1,416 SNPs by tagging functional SNPs selected from seven
distinct functional genomic annotations:DHSs, promoters,
50 UTRs, nonsynonymous SNPs in exons, 30 UTRs, introns,
and intergenic regions (Figure S2).We then tested these SNP
sets for enrichment in DHSs. Pre-defining functional SNPs
on the basis of specific driving annotations allowed us to
assess the ability of a method to identify true enrichment
and reject spurious overlap (Figure S3). Anappropriate strat-
egy should detect high DHS enrichment in sets designed to15
Figure 2. Comparison of Statistics between GoShifter and Matching-Based Tests
(A) We compared the performance of GoShifter with that of matching-based tests by using different parameters—(1) GEN, MAF, and TSS
proximity and (2) GEN, LD, TSS proximity, and TES proximity—to match SNPs on. We generated sets of 1,416 SNPs tagging SNPs over-
lapping different genomic annotations; some SNP sets tagging SNPs in specific annotations (e.g., DHSs, promoter regions, 50 UTRs, and
nonsynonymous variants in exons) were enriched in DHSs, whereas others (e.g., 30 UTRs, introns, and intergenic regions) were depleted
in DHSs. For each functional model, we generated 1,000 sets of SNPs that we subsequently tested for enrichment in DHSs (left). The
number of expected false positives at p < 0.05 is indicated by the dotted line. On the right, we plot the delta-overlap, which is the dif-
ference between the proportions of SNPs overlapping an annotation in the actual data and the proportion of SNPs overlapping an anno-
tation in the null distribution.
(B) We generated sets of 1,416 SNPs with variable proportions of variants within DHSs (increments of 5% and 1,000 sets per increment).
We compared the power to detect significant enrichment in DHSs for each increment (i.e., the proportion of significant SNP sets) be-
tween GoShifter and the best-performing matching-based strategy (GEN, LD, TSS proximity, and TES proximity) for two significance
levels (p < 0.05 and p < 0.001).
(C) To test the performance of GoShifter, we generated sets of 1,416 SNPs with varying proportions of variants in either exons or DHSs
(with increments of 5% in either annotation and 1,000 sets per increment). We then used GoShifter to analyze the enrichment (at
p < 0.001) in DHSs stratified on exons (upper panel) and vice versa (lower panel).tag functional variants in regulatory regions (DHSs, pro-
moters, and 50 UTRs), modest enrichment in nonsynony-
mous variants in exons and 30 UTRs (which colocalize
withDHSs),16,17 andno enrichment at introns or intergenic
regions (Material and Methods).
We observed that GoShifter was well powered to detect
significant enrichment in simulated SNP sets that tagged
variants in DHSs, promoters, and 50 UTRs: 100% of such
SNP sets obtained p < 0.001 according to 1,000 shifting it-
erations (Figure 2A; Figure S4). By chance, we would expect
5% of the SNP sets tagging variants in intronic and inter-
genic regions to obtain p < 0.05; indeed, we observed
that 4.44% and 7.4%, respectively, obtained p < 0.05
(Figure 2A; Table S3). The SNP sets tagging 30 UTRs and
nonsynonymous variants appropriately showed modest
enrichment (60% and 11% of these SNP sets, respectively,
obtained p < 0.05).The AThe analyses to benchmark GoShifter were based on
simulated GWAS SNP sets ascertained from a commercial
array. To assess whether ascertaining tag SNPs from com-
mercial genotyping arrays would affect observed statistics,
we also evaluated GoShifter’s performance by using
sequencing SNPs (from the 1000 Genomes Project).21 We
observed no significant difference for GoShifter’s perfor-
mance under genotyping or sequencing scenarios
(Figure S5). This indicates that GoShifter’s performance is
robust to the intrinsic biases in SNP ascertainment of com-
mercial genotyping arrays.
We then compared the results of GoShifter to those of
the more commonly used matching-based enrichment
tests2,5,7–10,12,13,19,29,31–38 (Table S1). These methods typi-
cally match SNPs on GEN, MAF, and TSS prox-
imity.2,7,12,13,19,32,35 We observed that when we matched
SNPs on these parameters, all simulated SNP sets,merican Journal of Human Genetics 97, 139–152, July 2, 2015 143
including 100% of those with functional variants derived
from intergenic regions, obtained p< 0.05 for DHS enrich-
ment (Figure 2A; Table S3). This suggests that selecting var-
iants on GEN, MAF, and TSS proximity might be insuffi-
cient to control false-positive rates in the assessment of
DHSs.
We then investigated whether matching on other com-
binations of SNP features was more effective. As expected,
we observed that the results were highly sensitive to the
choice of specific matching parameters. We noted that
the number of SNPs in LD was critical for appropriate sta-
tistical performance (Figure S4). Although MAF was
frequently included, it had little effect. We observed that
when SNPs were derived from 30 UTRs, matching on TES
proximity substantially decreased the inflated statistics.
Ultimately, we identified thatmatchingonthecombination
of GEN, TSS proximity, TES proximity, and LD adequately
controlled type I error if the SNPs were selected from non-
regulatory regions (e.g., intergenic or intronic regions).
After determining the best-performing SNP-matching
strategy, we wanted to more precisely quantify differences
in sensitivity between GoShifter andmatching-based tests.
For this purpose, we generated SNP sets where only a mi-
nority of variants tagged functional variants within
DHSs. We incremented the percentage of loci tagging func-
tional variants in the simulated SNP set by 3%. These sim-
ulations represented a test of the methods for detecting
enrichment under a range of more-challenging circum-
stances. For a set in which 10% of SNPs tagged DHSs,
GoShifter had 55% power to detect enrichment, but only
31% power with stringent SNP matching (Figure 2B). For
a set in which 10% of SNPs tagged DHSs, GoShifter had
55% power to detect enrichment, but only 31% power
with stringent SNP matching (Figure 2B).
Stratified Analysis Distinguishes Effects
of Colocalizing Annotations
To test the ability of GoShifter to control for the effects of
colocalized annotations, we examined two scenarios.
First, we tested the enrichment of different annotations
in 1,000 sets of 1,416 SNPs tagging exonic variants.
Although we observed significant enrichment of exons
across all SNP sets (p< 0.05), 60% also showed DHS enrich-
ment (Figure 2A). This secondary enrichment was a result
of colocalization between the DHSs and exons.16,17 Testing
for DHS enrichment after stratifying on exons resulted in a
much lower type I error rate, such that 10.2% of SNP sets
obtained p < 0.05. Similarly, at a more stringent signifi-
cance level (p < 0.001), we observed DHS enrichment in
12.5% of the SNP sets and 0.7% after stratifying on exons
(Figure 2C).
Second, we assessed 1,000 sets of 1,416 SNPs defined to
tag variants within DHSs. DHSs tend to overlap regions
mapped by H3K4me3 because they both colocalize with
active promoter regions. When testing for enrichment,
we would therefore expect to observe significant signal
for both of these annotations. However, because we144 The American Journal of Human Genetics 97, 139–152, July 2, 20know that functional signals were drawn from DHSs, an
adequate method should not detect significant enrich-
ment in H3K4me3 when it is stratified on the lead signal
from DHSs. Whereas all SNP sets were enriched in DHSs
at p < 0.05, 98% of the SNP sets were also enriched in
H3K4me3 sites (a histone mark known to highlight pro-
moters and colocalize with DHSs). As expected, after we
stratified on DHSs, only 1.3% of the SNP sets showed
H3K4me3 enrichment at p < 0.05, confirming that
H3K4me3 enrichment is entirely dependent onDHS coloc-
alization. Conversely, when tested for DHS enrichment
stratifying on H3K4me3, 100% of the SNP sets remained
significant. This confirmed that signal in H3K4me3 was
primarily explained by the DHS enrichment.
The stratified analysis modestly reduced power to detect
enrichment effects: for SNP sets where functional variants
were selected from both DHSs and exons, stratifying on
exons reduced power to detect DHS enrichment at p <
0.001 only when %20% of the functional variants were
from DHSs (Figure 2C). However, stratifying on DHSs did
not limit the power to detect exon enrichment.
We also assessed whether SNP-matching approaches
effectively account for colocalization of annotations. We
again considered the sets of DHS-tagging SNPs and tested
for H3K4me3 enrichment. To control for the DHS effect,
we used the most appropriate matching strategy (GEN,
TSS proximity, TES proximity, and LD) and included an ex-
tra matching parameter (DHS). We observed that 100% of
SNP sets still obtained H3K4me3 enrichment at p < 0.05.
We concluded that SNP-matching tests cannot easily con-
trol for colocalization of annotations (Figure S6).
GoShifter Effectively Annotates eQTL SNPs
As a proof of concept, we applied our approach to eQTL
variants, given that eQTLs are known to localize close to
TSSs and to be enriched in DHSs.39–43
First, we used GoShifter to assess the enrichment of
eQTLs in DHSs at various distances to the TSS (Figure 3A),
various histone marks (H3K9ac, H3K4me3, and H3K4me1)
associated with active gene regulation, and genes
(Figure 3B). We also included 30 UTRs because they have
been previously suggested to independently account for
a proportion of eQTL signal.29,39 We observed that each
of these annotations was enriched in eQTLs (p < 0.05).
To better localize the source of enrichment with respect
to the TSS, we stratified the TSS-distance window for
DHSs; we observed only significant results within 500 bp
of the TSS (p¼ 23 104; Figure 3A), consistent with earlier
studies. We then assessed the enrichment of the other
annotations while stratifying for DHSs. We observed that
the enrichment for genes and each of the histone marks,
with the exception of H3K4me1 (p ¼ 0.02) and 30 UTRs
(p ¼ 6 3 103), became insignificant (Figure 3B). However,
DHS enrichment remained significant after we stratified on
each of the annotations, indicating that eQTLs are en-
riched in DHSs independently of the other annotations.
This suggests that eQTLs might act through mechanisms15
Figure 3. eQTL Variants Localize to DHSs near TSSs
(A) To test the performance of GoShifter on real data, we analyzed the enrichment of 6,380 eQTLs with local DHSs at various distances
(varying between 0.5 and 50 kb) to the TSS by using 10,000 random shifts. The p values for each analysis are in the top panel, and the
delta-overlap measures are in the bottom panel (a higher value denotes a higher proportion of significant loci than in the null
distribution).
(B) We tested enrichment of these eQTLs in various other regulatory marks (H3K9ac, H3K4me3 H3K4me1, and DHSs) associated with
active transcription (10,000 random shifts) and overlap with genes and 30 UTRs. We tested each annotation in an unstratified analysis,
and we also tested for enrichment stratifying on each of the other annotations. When we tested for gene-transcript enrichment by strat-
ifying on regulatory annotations, negative delta-overlap values indicated that eQTL SNPs were primarily captured by the regulatory an-
notations and depleted in gene transcripts (except for 30 UTRs).independent of genetic variation in DHSs. For 30 UTRs,
these mechanisms might include alterations in miRNA
binding sites.44–46
Quantifying the Proportion of GWAS Catalog SNPs
with DHS Causal Variants
We assessed 1,416 independent SNP associations from
the NHGRI GWAS Catalog25 for overlap with different an-
notations (Material and Methods). We observed enrich-
ment at DHSs (p < 104), at genes, at H3K4me3 and
H3K4me1 marks, and also at 5- and 10-kb windows
around TSSs (Figure 4A). Pairwise stratified tests showed
that DHSs were enriched independently of other annota-
tions (p% 7 3 104). In contrast, the enrichment of gene
transcripts and TSSs was not significant after stratification
on DHSs. Both H3K4me1 and H3K4me3 retained nomi-
nal enrichment independently of each other and DHSs
(p % 0.05; Figure 4B). These results suggest that causal
disease-associated variants in DHSs and H3K4me3 and
H3K4me1 marks function through three independent
mechanisms.
We aimed to accurately determine the proportion of
GWAS loci that tag variants in DHSs by using theThe AGoShifter-derived delta-overlap parameter (Material and
Methods), which quantifies the strength of observed
enrichment (Figure S1). We calculated the delta-overlap
for the GWAS Catalog SNPs and DHSs to be 3.17%
(Figure 4C). We then sought to infer the proportion of
loci that overlap DHSs from the observed delta-overlap
value. We simulated 1,000 SNP sets (the same size as the
GWAS Catalog set) with 0%–45% of causal variants in
DHSs by using 3% increments and calculated their corre-
sponding delta-overlap values. We selected simulated sets
that had a delta-overlap within the range of that of the
GWAS Catalog (delta-overlap 5 0.2) and created a proba-
bility distribution of the proportion of causal variants
within DHSs. From this distribution, we estimated the
mean and 95% confidence interval for the proportion of
causal variants in DHSs for the GWAS Catalog. We deter-
mined that the delta-overlap of 3.17% corresponded to
15%–36% causal variants in DHSs (95% confidence;
Figure 4D). Recent studies have estimated that around
80% of trait-associated variants (or the SNPs in LD) within
the GWAS Catalog overlap DHSs2,12,13; our estimates sug-
gest that DHS enrichment might bemoremodest than pre-
viously reported.merican Journal of Human Genetics 97, 139–152, July 2, 2015 145
Figure 4. Quantifying the Proportion of Causal GWAS Catalog Variants Derived from DHSs
(A) We assessed the enrichment of 1,416 independent GWAS Catalog SNPs in various genomic annotations by using GoShifter with
10,000 local shifts. We observed strong enrichment of DHSs (p < 104) and nominal enrichment (p < 0.05, yellow line) of
H3K4me3, H3K4me1, genes, and distance to the TSS (5 and 10 kb).
(B) We performed pairwise stratified analysis for significantly enriched annotations. DHSs showed a strong residual enrichment (p< 73
104) after stratification on each of the other annotations.
(C) We generated sets of 1,416 SNPs overlapping an increasing proportion of DHSs (5% increments and 1,000 sets per increment) and
determined the delta-overlap per set, yielding a delta-overlap distribution per DHS-overlap increment. We then determined the delta-
overlap for the real GWAS Catalog to be 3.17 (dotted line), which corresponds to 15%–36% of loci with causal variants within DHSs
(D) within the 95% confidence interval.RA and Breast Cancer Associations Are Enriched at the
Summits of Cell-Type-Specific Histone Marks
We examined two phenotypes to test GoShifter’s ability to
identify cell-type-specific functional variants. To ensure
that GoShifter was powered to detect significant enrich-
ments (Figure S7), we selected phenotypes with over 50
associated variants at the commonly applied genome-
wide significance threshold (p < 5 3 108). We first tested
88 SNPs associated with RA27 for enrichment of H3K4me3.
We focused on CD4þmemory T cells given recent observa-
tions of cell-type-specific gene expression and eQTLs
within these loci.1,47,48 We observed no enrichment146 The American Journal of Human Genetics 97, 139–152, July 2, 20(p ¼ 0.17) when we used the peak bodies of H3K4me3 in
either CD4þ memory T cells (p ¼ 0.17) or in an aggregate
of all 118 cell types from our datasets (p ¼ 0.14;
Figure 5A). Because the median width of H3K4me3 peak
bodies varied widely (110–86,490 bp), we examined the
summit regions (5100 bp from the H3K4me3 summits),
where active gene-regulatory elements are most likely
located.49 In the summit regions, we observed significant
enrichment both in the 118 aggregate cell types (p ¼
0.044) and in CD4þ memory T cells specifically (p ¼ 1.6 3
103). The CD4þmemory Tcell signal remained significant
after stratification on the summit regions of the other 11715
Figure 5. Enrichment Results for Three Selected Sets of Trait-Associated SNPs
(A) We examined the enrichment of 88 RA-associated variants with H3K4me3 in CD4þ T memory cells and in an aggregate of 118
different cell types and tissues. We assessed raw peaks (peak bodies) and summit regions (5100 bp from the summit). We observed a
nominally significant enrichment in the aggregate of cell types and tissues (p ¼ 0.044) and a pronounced enrichment within CD4þ
T memory cells (p ¼ 1.6 3 103). Stratified analysis indicated that the enrichment signal was driven by CD4þ T memory cells: the
significance of the cell-type-aggregate enrichment decreased (p ¼ 0.08) when we stratified on CD4þ T cells, but not vice versa (p ¼
2.7 3 103).
(B) We assessed the enrichment of 69 breast-cancer-associated variants with various histone marks (H3K4me3 and H3K4me1) in the 118
tissues and cell types. Breast-cancer-associated SNPs were highly enriched (p ¼ 2 3 103) in summit regions of H3K4me1 peaks in
vHMECs (left panel), but not in other cells, H3K4me3 summit regions (p > 0.4), or H3K4me1 peak bodies. The stratified enrichment
analysis indicated that the enrichment of H3K4me1 summit regions in vHMECs was independent of the H3K4me1 summit regions
in the aggregated cell types and tissues. The H3K4me1 enrichment in vHMECs within summit regions was maintained when we strat-
ified on summit regions from other breast tissues and cell types (p < 3.6 3 103; right panel).
(C) Similarly, we assessed enrichment of 697 SNPs associated with height in DHSs from 217 different tissues. The height-associated SNPs
showed the highest enrichment of DHSs in embryonic stem cells (p < 104) and CD3þ cells (p < 104) from cord blood (left panel).
However, the CD3þ cell DHS enrichment diminished after stratification on embryonic stem cells (p ¼ 0.08), whereas embryonic
stem cells retained significance after stratification on CD3þ cells (p ¼ 9.6 3 103; right panel).cell types (p ¼ 2.7 3 103). In contrast, the other cell types
did not retain significant enrichment after stratification
on CD4þ memory T cells (p ¼ 0.08). These results suggest
that H3K4me3 summit regions in CD4þ memory T cells
could help prioritize causal variants in RA-associated loci.The ASimilarly, we examined 69 SNPs28 associated with
breast cancer for enrichment of H3K4me3. Summit re-
gions were not enriched (p > 0.4) in any of the three
breast tissues present in our dataset. We therefore tested
for enrichment of another active regulatory mark,merican Journal of Human Genetics 97, 139–152, July 2, 2015 147
H3K4me1, for which there were four breast tissues in our
dataset. The peak bodies of this mark were nominally en-
riched (p ¼ 0.034) only in breast myoepithelial cells.
However, when we used H3K4me1 summit regions, we
observed significant enrichment (p ¼ 2 3 103) in
variant human mammary epithelial cells (vHMECs;
Figure 5B). We performed pairwise stratified enrichment
tests across the four breast tissues and found that the
vHMEC summit regions retained significance (p <
3.6 3 103) after stratification on peak summits from
each of the other three breast tissues. We found that
none of the DHS samples in our dataset showed nomi-
nally significant enrichment.
Stratified Analysis Can Indicate Relevant Cell Types
for Height
We assessed 697 SNPs associated with adult human
height,26 a highly polygenic trait without clearly estab-
lished relevant cell types. When we examined aggregated
DHSs from 217 cell types collectively, we observed nomi-
nal evidence of overlap (p¼ 0.019). Individually, many tis-
sues, including 13 at p < 103, demonstrated some evi-
dence of overlap (Figure 5C). We observed the strongest
enrichment (p< 104) in embryonic stem cells (H1-hESCs)
and primary CD3þ cells from cord blood. The enrichment
in H1-hESCs remained significant after stratification on
cord-blood CD3þ cells (p ¼ 9.6 3 103), but the converse
enrichment (p ¼ 0.08) did not. These results suggest that
examining DHSs in embryonic stem cells or a related cell
type might be informative for fine mapping height-associ-
ated loci for potential causal variants.
The Locus Overlap Score Can Be Used for Prioritizing
Trait-Associated Loci
After the most significantly enriched annotations are iden-
tified, the loci contributing the most to such enrichment
are those with the lowest overlap score (Figure S8). A locus
that obtains a low overlap score would typically have only
a few variants linked to the index SNP and sparse density of
the annotation. These are the loci where variants might be
most effectively prioritized.
For example, in breast cancer, the locus with the best
(lowest) overlap score (0.097) was rs889312 (Figure 6).
That SNP is in LD with seven other variants, of which
only rs1862626 overlaps a vHMEC H3K4me1 summit re-
gion. This SNP is upstream of MAP3K1 (MIM: 600982)
and modifies a predicted binding site for estrogen recep-
tor alpha (ER-a),50 consistent with the well-established
role of estrogen-mediated signaling in breast cancer pro-
gression.51,52 For height, rs11677466 showed the best
overlap score (0.026; Figure 6). This SNP itself overlaps
an embryonic stem cell DHS that is a known binding
site for HNF4a,53–55 a transcription factor that plays
important roles in metabolic regulation and stem cell dif-
ferentiation. Functional follow-up will be necessary to
further validate these variants. The specific annotations
indicate the type of regulatory element driving these as-148 The American Journal of Human Genetics 97, 139–152, July 2, 20sociations and define the cell type in which they are
active.Discussion
Here, we have presented GoShifter, a method that enables
the identification of annotations that are the most infor-
mative in distinguishing causal variants from associated
ones. GoShifter stringently controls for local features by
shifting annotations within trait-associated loci. Our
method represents an important advance over current ap-
proaches in its ability to assess independent effects from
colocalizing annotations.
GoShifter is suited to investigate whether a specific
annotation might be effective in fine mapping known ge-
netic loci for a trait. Consequently, GoShifter does tend to
favor high-resolution annotations (e.g., annotations with a
small average size). But in certain instances, large annota-
tions (e.g., super enhancers or large gene sets) might be
important indicators that separate trait-associated varia-
tion from non-trait-associated variation.56 Although
informative, these annotations might not be particularly
effective for fine mapping. Under these circumstances,
SNP matching might be a necessity. We note with caution,
however, that the importance of individual matching pa-
rameters might be different depending on which specific
annotations are being tested. Importantly, matching on
the number of SNPs in LD will be critical: the number of
SNPs that a variant is in LD with will be proportional to
the chance that one of those variants overlaps an annota-
tion; consequently, failing to control for LD invariably
yields inflated results. In certain instances, controlling for
LD alone might substantially mitigate type I error, but in
most instances, matching on LD alone will not be
adequate. Additional parameters should be carefully
considered and evaluated (e.g., by simulation experiments)
when SNP-matching-based enrichment tests are used. For
example, in the assessment of DHS enrichment, our results
demonstrate that GEN, TSS proximity, and TES proximity
are additional important parameters. We speculate that
to accurately detect the enrichment in exons, it might be
necessary to further match on other parameters, such as
the number of exons and gene length.
In this study, we examined variants in LD (r2 > 0.8) with
an index SNP for overlap with an annotation. This is a
widely used approach, but it has limitations. In many in-
stances, index SNPs within loci that have been detected
by sparse genotyping or in relatively smaller studies have
a lower degree of linkage than r2 > 0.8 to a causal variant.
This is particularly true in complex genetic regions, where
multiple haplotypes might be driving an association, such
as within themajor histocompatibility complex in autoim-
mune diseases57 or IRF5 (MIM: 607218) in systemic lupus
erythematosus.58 One approach to increasing the sensi-
tivity of enrichment methods would be to weight annota-
tion overlaps by the posterior probabilities that associated15
Figure 6. Locus Plots Showing the Peaks, Variants, and Reads in Two Trait-Associated Loci
(A) The SNP rs889312 defines the locus with the best overlap score among breast cancer SNP associations. This SNP is in LD (r2 > 0.8)
with a variant (rs1862626) that overlaps the summit region of an H3K4me1 peak. This peak overlaps a predicted ER-a binding site. The
associated locus is located upstream of potential oncogene MAP3K1.
(B) Of the height-associated SNPs, rs11677466 defines the locus with the best overlap score and is located in an exon of DIS3L2 (MIM:
614184). This SNP overlaps a DHS peak, which also overlaps a known HNF4a binding site.SNPs are the individual causal SNPs.59 GoShifter can be
used again tomake significance assessments by shifting an-
notations and reassessing weighted overlap to define a null
distribution.
We present examples to illustrate how stratified analysis
might help to determine whether fundamentally different
functions (such as regulatory versus coding variation)
might be driving complex-disease associations. In many
instances, different annotations colocalize because they
are derived from different molecular assays that query
the same genomic functional process. For example,
H3K4me1 marks and bidirectional transcription60 are
both signatures of enhancers. In these instances, stratified
analysis can be used to determine assays or cell types withThe Athemost informative annotations. Indeed, it could even be
the case that multiple assays are independently informa-
tive, and combining them could be the most powerful
approach. Stratified analysis offers not only a clear strategy
for evaluating individual annotations against each other
but also for assessing whether combinations of annota-
tions are more informative than any individual
annotation.
Applying GoShifter, we observed that different annota-
tions play dominant roles in different complex traits. The
eQTL results have highlighted that in addition to gene-reg-
ulatory regions and protein-coding genes, other mecha-
nisms might be mediating causal variation for complex
phenotypes. The observed enrichment of 30 UTRs in eQTLsmerican Journal of Human Genetics 97, 139–152, July 2, 2015 149
suggests that post-transcriptional gene regulation is one
such mechanism by which genomic variation affects
gene-transcript levels. Other functional genomic features,
such as non-coding RNAs and copy-number variation,
could also be driving complex phenotypic and disease vari-
ation.39,44–46
Our results indicate that SNPs represented in the GWAS
Catalog are globally enriched within DHSs. However, this
is not representative of enrichment for individual pheno-
types and in fact might be driven by a selection of pheno-
types with a large number of associated variants. When we
applied GoShifter to variants associated with height, we
observed strong DHS enrichment specifically in embryonic
stem cells, whereas breast cancer variants were enriched in
H3K4me1 but not DHSs. These could be partly due to the
fact that different trait-relevant tissues were mapped with
different assays. Nevertheless, variants associated with
different phenotypes are likely to act through various
mechanisms, resulting in differential enrichment of anno-
tations. These results also show that our stratified approach
can be applied to narrow down the specific cell type in
which disease-associated variants function, even from
within a single disease tissue of interest. The strong enrich-
ment of breast-cancer- and RA-associated loci within the
summit regions of histone marks is consistent with the
well-described functional significance of the summit re-
gions.49
We expect that the applicability of GoShifter will
expand as relevant functional annotations increase over
time. Once our approach identifies independently infor-
mative functional annotations by analyzing a large set of
associated variants, a powerful aspect of GoShifter is the
ability to identify the specific loci that drive the enrich-
ment statistics. Combining the identification of the func-
tional annotations associated with a trait and the identifi-
cation of the loci that drive that association should
facilitate effective and focused experimental interrogation
of these loci.
Software is available as the GoShifter package, written in
Python-2.7.Supplemental Data
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ajhg.2015.05.016.Acknowledgments
We acknowledge the GIANT consortium for providing us access
to the height SNPs. We also acknowledge Joel Hirschhorn, X. Shir-
ley Liu, Mark Daly, Tonu Esko, Dorothee Diogo, and Joshua
Randall for helpful scientific discussions. This work was
supported by funding from the NIH (NIAMS-1R01AR063759
[S.R.], 1UH2AR067677-01 [S.R.], 1U19AI111224-01 [S.R.], and
NHGRI-1U01HG0070033 [R.J.K.]), a Doris Duke Clinical Scientist
Development Award (S.R.), the Rubicon grant from the150 The American Journal of Human Genetics 97, 139–152, July 2, 20Netherlands Organization for Scientific Research (G.T.), and the
Wellcome Trust Sanger Institute (WT098051 [G.T.]).
Received: March 9, 2015
Accepted: May 26, 2015
Published: July 2, 2015Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://www.1000genomes.org/
GoShifter, http://www.broadinstitute.org/mpg/goshifter/
OMIM, http://www.omim.org/
UCSC Genome Browser, http://genome.ucsc.edu/References
1. Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B.E., Liu, X.S.,
and Raychaudhuri, S. (2013). Chromatin marks identify crit-
ical cell types for fine mapping complex trait variants. Nat.
Genet. 45, 124–130.
2. Maurano,M.T.,Humbert, R., Rynes,E., Thurman,R.E.,Haugen,
E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J.,
et al. (2012). Systematic localizationof commondisease-associ-
ated variation in regulatory DNA. Science 337, 1190–1195.
3. Adrianto, I., Wen, F., Templeton, A., Wiley, G., King, J.B., Les-
sard, C.J., Bates, J.S., Hu, Y., Kelly, J.A., Kaufman, K.M., et al.;
BIOLUPUS and GENLES Networks (2011). Association of a
functional variant downstream of TNFAIP3 with systemic
lupus erythematosus. Nat. Genet. 43, 253–258.
4. Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E.,
Ahfeldt, T., Sachs, K.V., Li, X., Li, H., Kuperwasser, N., Ruda,
V.M., et al. (2010). From noncoding variant to phenotype
via SORT1 at the 1p13 cholesterol locus. Nature 466, 714–719.
5. Cowper-Sal lari, R., Zhang, X., Wright, J.B., Bailey, S.D., Cole,
M.D., Eeckhoute, J., Moore, J.H., and Lupien, M. (2012). Breast
cancer risk-associated SNPs modulate the affinity of chromatin
forFOXA1andaltergeneexpression.Nat.Genet.44, 1191–1198.
6. Harismendy, O., Notani, D., Song, X., Rahim, N.G., Tanasa, B.,
Heintzman, N., Ren, B., Fu, X.D., Topol, E.J., Rosenfeld, M.G.,
and Frazer, K.A. (2011). 9p21 DNA variants associated with
coronary artery disease impair interferon-g signalling
response. Nature 470, 264–268.
7. Karczewski, K.J., Dudley, J.T., Kukurba, K.R., Chen, R., Butte,
A.J., Montgomery, S.B., and Snyder, M. (2013). Systematic
functional regulatory assessment of disease-associated vari-
ants. Proc. Natl. Acad. Sci. USA 110, 9607–9612.
8. Liu, J.Z., Almarri, M.A., Gaffney, D.J., Mells, G.F., Jostins, L.,
Cordell, H.J., Ducker, S.J., Day, D.B., Heneghan, M.A., Neu-
berger, J.M., et al.; UK Primary Biliary Cirrhosis (PBC) Con-
sortium; Wellcome Trust Case Control Consortium 3 (2012).
Dense fine-mapping study identifies new susceptibility loci
for primary biliary cirrhosis. Nat. Genet. 44, 1137–1141.
9. Pasquali, L., Gaulton, K.J., Rodrı´guez-Seguı´, S.A., Mularoni, L.,
Miguel-Escalada, I., Akerman, I., Tena, J.J., Mora´n, I., Go´mez-
Marı´n, C., van de Bunt, M., et al. (2014). Pancreatic islet
enhancer clusters enriched in type 2 diabetes risk-associated
variants. Nat. Genet. 46, 136–143.
10. Paul, D.S., Albers, C.A., Rendon, A., Voss, K., Stephens, J., van
der Harst, P., Chambers, J.C., Soranzo, N., Ouwehand, W.H.,
and Deloukas, P.; HaemGen Consortium (2013). Maps of15
open chromatin highlight cell type-restricted patterns of reg-
ulatory sequence variation at hematological trait loci.
Genome Res. 23, 1130–1141.
11. Pickrell, J.K. (2014). Joint analysis of functional genomic data
and genome-wide association studies of 18 human traits. Am.
J. Hum. Genet. 94, 559–573.
12. Schaub, M.A., Boyle, A.P., Kundaje, A., Batzoglou, S., and
Snyder, M. (2012). Linking disease associations with regulato-
ry information in the human genome. Genome Res. 22, 1748–
1759.
13. Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A.,
Doyle, F., Epstein, C.B., Frietze, S., Harrow, J., Kaul, R., et al.;
ENCODE Project Consortium (2012). An integrated encyclo-
pedia of DNA elements in the human genome. Nature 489,
57–74.
14. Bernstein, B.E., Stamatoyannopoulos, J.A., Costello, J.F., Ren,
B.,Milosavljevic, A.,Meissner, A., Kellis,M.,Marra,M.A., Beau-
det, A.L., Ecker, J.R., et al. (2010). TheNIHRoadmapEpigenom-
ics Mapping Consortium. Nat. Biotechnol. 28, 1045–1048.
15. Adams, D., Altucci, L., Antonarakis, S.E., Ballesteros, J., Beck,
S., Bird, A., Bock, C., Boehm, B., Campo, E., Caricasole, A.,
et al. (2012). BLUEPRINT to decode the epigenetic signature
written in blood. Nat. Biotechnol. 30, 224–226.
16. Mercer, T.R., Edwards, S.L., Clark, M.B., Neph, S.J., Wang, H.,
Stergachis, A.B., John, S., Sandstrom, R., Li, G., Sandhu, K.S.,
et al. (2013). DNase I-hypersensitive exons colocalize with
promoters and distal regulatory elements. Nat. Genet. 45,
852–859.
17. Birnbaum, R.Y., Clowney, E.J., Agamy, O., Kim, M.J., Zhao, J.,
Yamanaka, T., Pappalardo, Z., Clarke, S.L., Wenger, A.M.,
Nguyen, L., et al. (2012). Coding exons function as tissue-spe-
cific enhancers of nearby genes. Genome Res. 22, 1059–1068.
18. Bickel, P.J., Boley, N., Brown, J.B., Huang, H., and Zhang, N.R.
(2010). Subsampling methods for genomic inference. Ann.
Appl. Stat. 4, 1660–1697.
19. Khurana, E., Fu, Y., Colonna, V., Mu, X.J., Kang, H.M., Lappa-
lainen, T., Sboner, A., Lochovsky, L., Chen, J., Harmanci, A.,
et al.; 1000 Genomes Project Consortium (2013). Integrative
annotation of variants from 1092 humans: application to can-
cer genomics. Science 342, 1235587.
20. Sankararaman, S., Mallick, S., Dannemann, M., Pru¨fer, K.,
Kelso, J., Pa¨a¨bo, S., Patterson, N., and Reich, D. (2014). The
genomic landscape of Neanderthal ancestry in present-day
humans. Nature 507, 354–357.
21. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Dur-
bin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and
McVean, G.A.; 1000 Genomes Project Consortium (2012).
An integrated map of genetic variation from 1,092 human ge-
nomes. Nature 491, 56–65.
22. Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S.,
Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li,
W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq
(MACS). Genome Biol. 9, R137.
23. Raychaudhuri, S., Plenge, R.M., Rossin, E.J., Ng, A.C., Purcell,
S.M., Sklar, P., Scolnick, E.M., Xavier, R.J., Altshuler, D., and
Daly, M.J.; International Schizophrenia Consortium (2009).
Identifying relationships among genomic disease regions: pre-
dicting genes at pathogenic SNP associations and rare dele-
tions. PLoS Genet. 5, e1000534.
24. Ng, P.C., and Henikoff, S. (2003). SIFT: Predicting amino acid
changes that affect protein function. Nucleic Acids Res. 31,
3812–3814.The A25. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Jun-
kins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., and
Parkinson, H. (2014). The NHGRI GWAS Catalog, a curated
resource of SNP-trait associations. Nucleic Acids Res. 42,
D1001–D1006.
26. Wood, A.R., Esko, T., Yang, J., Vedantam, S., Pers, T.H., Gustafs-
son, S., Chu, A.Y., Estrada, K., Luan, J., Kutalik, Z., et al.; Elec-
tronic Medical Records and Genomics (eMEMERGEGE)
Consortium; MIGen Consortium; PAGEGE Consortium; Life-
Lines Cohort Study (2014). Defining the role of common vari-
ation in the genomic and biological architecture of adult
human height. Nat. Genet. 46, 1173–1186.
27. Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Ko-
chi, Y., Ohmura, K., Suzuki, A., Yoshida, S., et al.; RACI con-
sortium; GARNET consortium (2014). Genetics of rheumatoid
arthritis contributes to biology and drug discovery. Nature
506, 376–381.
28. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Boje-
sen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer Suscep-
tibility Collaboration; Hereditary Breast and Ovarian Cancer
Research Group Netherlands (HEBON); kConFab Investiga-
tors; Australian Ovarian Cancer Study Group; GENICA
(Gene Environment Interaction and Breast Cancer in Ger-
many) Network (2013). Large-scale genotyping identifies 41
new loci associated with breast cancer risk. Nat. Genet. 45,
353–361.e1–e2.
29. Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann,
C., Kettunen, J., Christiansen, M.W., Fairfax, B.P., Schramm,
K., Powell, J.E., et al. (2013). Systematic identification of trans
eQTLs as putative drivers of known disease associations. Nat.
Genet. 45, 1238–1243.
30. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
31. Gerasimova, A., Chavez, L., Li, B., Seumois, G., Greenbaum, J.,
Rao, A., Vijayanand, P., and Peters, B. (2013). Predicting cell
types and genetic variations contributing to disease by
combining GWAS and epigenetic data. PLoS ONE 8, e54359.
32. Lee, Y., Gamazon, E.R., Rebman, E., Lee, Y., Lee, S., Dolan,M.E.,
Cox,N.J., andLussier, Y.A. (2012). Variants affecting exon skip-
ping contribute to complex traits. PLoS Genet. 8, e1002998.
33. Anttila, V., Winsvold, B.S., Gormley, P., Kurth, T., Bettella, F.,
McMahon, G., Kallela, M., Malik, R., de Vries, B., Terwindt, G.,
et al.; North American Brain Expression Consortium; UK Brain
Expression Consortium; International Headache Genetics
Consortium (2013). Genome-wide meta-analysis identifies
new susceptibility loci for migraine. Nat. Genet. 45, 912–917.
34. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gus-
tafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich,
M.L., Mora, S., et al.; Global Lipids Genetics Consortium
(2013). Discovery and refinement of loci associated with lipid
levels. Nat. Genet. 45, 1274–1283.
35. Lappalainen, T., Sammeth,M., Friedla¨nder, M.R., ’t Hoen, P.A.,
Monlong, J., Rivas, M.A., Gonza`lez-Porta, M., Kurbatova, N.,
Griebel, T., Ferreira, P.G., et al.; Geuvadis Consortium (2013).
Transcriptome and genome sequencing uncovers functional
variation in humans. Nature 501, 506–511.
36. Akhtar-Zaidi, B., Cowper-Sal-lari, R., Corradin, O., Saiakhova,
A., Bartels, C.F., Balasubramanian,D.,Myeroff, L., Lutterbaugh,merican Journal of Human Genetics 97, 139–152, July 2, 2015 151
J., Jarrar, A., Kalady, M.F., et al. (2012). Epigenomic enhancer
profiling defines a signature of colon cancer. Science 336,
736–739.
37. Corradin, O., Saiakhova, A., Akhtar-Zaidi, B., Myeroff, L., Wil-
lis, J., Cowper-Sal lari, R., Lupien, M., Markowitz, S., and Sca-
cheri, P.C. (2014). Combinatorial effects of multiple enhancer
variants in linkage disequilibrium dictate levels of gene
expression to confer susceptibility to common traits. Genome
Res. 24, 1–13.
38. Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward,
L.D., Epstein, C.B., Zhang, X., Wang, L., Issner, R., Coyne,
M., et al. (2011). Mapping and analysis of chromatin state dy-
namics in nine human cell types. Nature 473, 43–49.
39. Brown, C.D., Mangravite, L.M., and Engelhardt, B.E. (2013).
Integrative modeling of eQTLs and cis-regulatory elements
suggests mechanisms underlying cell type specificity of
eQTLs. PLoS Genet. 9, e1003649.
40. Degner, J.F., Pai, A.A., Pique-Regi, R., Veyrieras, J.B., Gaffney,
D.J., Pickrell, J.K., De Leon, S., Michelini, K., Lewellen, N.,
Crawford, G.E., et al. (2012). DNase I sensitivity QTLs are a
major determinant of human expression variation. Nature
482, 390–394.
41. Gaffney, D.J., Veyrieras, J.B., Degner, J.F., Pique-Regi, R., Pai,
A.A., Crawford, G.E., Stephens, M., Gilad, Y., and Pritchard,
J.K. (2012). Dissecting the regulatory architecture of gene
expression QTLs. Genome Biol. 13, R7.
42. Stranger, B.E., Forrest, M.S., Dunning, M., Ingle, C.E., Beaz-
ley, C., Thorne, N., Redon, R., Bird, C.P., de Grassi, A., Lee,
C., et al. (2007). Relative impact of nucleotide and copy
number variation on gene expression phenotypes. Science
315, 848–853.
43. Veyrieras, J.B., Kudaravalli, S., Kim, S.Y., Dermitzakis, E.T., Gi-
lad, Y., Stephens, M., and Pritchard, J.K. (2008). High-resolu-
tion mapping of expression-QTLs yields insight into human
gene regulation. PLoS Genet. 4, e1000214.
44. Barreau, C., Paillard, L., and Osborne, H.B. (2005). AU-rich el-
ements and associated factors: are there unifying principles?
Nucleic Acids Res. 33, 7138–7150.
45. Pasquinelli, A.E. (2012). MicroRNAs and their targets: recogni-
tion, regulation and an emerging reciprocal relationship. Nat.
Rev. Genet. 13, 271–282.
46. Sandberg, R., Neilson, J.R., Sarma, A., Sharp, P.A., and Burge,
C.B. (2008). Proliferating cells express mRNAs with shortened
30 untranslated regions and fewer microRNA target sites.
Science 320, 1643–1647.
47. Hu, X., Kim, H., Raj, T., Brennan, P.J., Trynka, G., Teslovich,
N., Slowikowski, K., Chen, W.M., Onengut, S., Baecher-
Allan, C., et al. (2014). Regulation of gene expression in
autoimmune disease loci and the genetic basis of prolifera-
tion in CD4þ effector memory T cells. PLoS Genet. 10,
e1004404.152 The American Journal of Human Genetics 97, 139–152, July 2, 2048. Hu, X., Kim, H., Stahl, E., Plenge, R., Daly, M., and Raychaud-
huri, S. (2011). Integrating autoimmune risk loci with gene-
expression data identifies specific pathogenic immune cell
subsets. Am. J. Hum. Genet. 89, 496–506.
49. Pepke, S.,Wold, B., andMortazavi, A. (2009). Computation for
ChIP-seq and RNA-seq studies. Nat. Methods 6 (11, Suppl),
S22–S32.
50. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for
exploring chromatin states, conservation, and regulatory
motif alterationswithin sets of genetically linked variants. Nu-
cleic Acids Res. 40, D930–D934.
51. Folkerd, E.J., and Dowsett, M. (2010). Influence of sex hor-
mones on cancer progression. J. Clin. Oncol. 28, 4038–4044.
52. Jordan, V.C. (2004). Selective estrogen receptor modulation:
concept and consequences in cancer. Cancer Cell 5, 207–213.
53. McDonald, T.J., and Ellard, S. (2013). Maturity onset diabetes
of the young: identification and diagnosis. Ann. Clin. Bio-
chem. 50, 403–415.
54. Santangelo, L.,Marchetti, A., Cicchini, C., Conigliaro, A., Conti,
B.,Mancone, C., Bonzo, J.A., Gonzalez, F.J., Alonzi, T., Amicone,
L., andTripodi,M. (2011).Thestable repressionofmesenchymal
program is required for hepatocyte identity: a novel role for he-
patocyte nuclear factor 4a. Hepatology 53, 2063–2074.
55. DeLaForest, A., Nagaoka, M., Si-Tayeb, K., Noto, F.K., Ko-
nopka, G., Battle, M.A., and Duncan, S.A. (2011). HNF4A is
essential for specification of hepatic progenitors from human
pluripotent stem cells. Development 138, 4143–4153.
56. Vahedi, G., Kanno, Y., Furumoto, Y., Jiang, K., Parker, S.C., Er-
dos, M.R., Davis, S.R., Roychoudhuri, R., Restifo, N.P., Gadina,
M., et al. (2015). Super-enhancers delineate disease-associated
regulatory nodes in T cells. Nature 520, 558–562.
57. de Bakker, P.I., and Raychaudhuri, S. (2012). Interrogating the
major histocompatibility complex with high-throughput ge-
nomics. Hum. Mol. Genet. 21 (R1), R29–R36.
58. Graham, R.R., Kozyrev, S.V., Baechler, E.C., Reddy, M.V.,
Plenge, R.M., Bauer, J.W., Ortmann, W.A., Koeuth, T., Gonza´-
lez Escribano, M.F., Pons-Estel, B., et al.; Argentine and Span-
ish Collaborative Groups (2006). A common haplotype of
interferon regulatory factor 5 (IRF5) regulates splicing and
expression and is associated with increased risk of systemic
lupus erythematosus. Nat. Genet. 38, 550–555.
59. Maller, J.B., McVean, G., Byrnes, J., Vukcevic, D., Palin, K., Su,
Z., Howson, J.M., Auton, A., Myers, S., Morris, A., et al.; Well-
come Trust Case Control Consortium (2012). Bayesian refine-
ment of association signals for 14 loci in 3 common diseases.
Nat. Genet. 44, 1294–1301.
60. Forrest, A.R., Kawaji, H., Rehli, M., Baillie, J.K., de Hoon, M.J.,
Haberle, V., Lassmann, T., Kulakovskiy, I.V., Lizio, M., Itoh,M.,
et al.; FANTOM Consortium and the RIKEN PMI and CLST
(DGT) (2014). A promoter-level mammalian expression atlas.
Nature 507, 462–470.15
